BRPI0508982A - uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 - Google Patents
uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11Info
- Publication number
- BRPI0508982A BRPI0508982A BRPI0508982-4A BRPI0508982A BRPI0508982A BR PI0508982 A BRPI0508982 A BR PI0508982A BR PI0508982 A BRPI0508982 A BR PI0508982A BR PI0508982 A BRPI0508982 A BR PI0508982A
- Authority
- BR
- Brazil
- Prior art keywords
- azd2171
- cpt
- human
- maleate salt
- warm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
USO DE AZD2171 PU DE UM SAL DESTE FARMACEUTICAMENTE ACEITáVEL EXCLUINDO UM SAL DE MALETO DE AZD2171, COMPOSIçãO FARMACêUTICA, KIT, MéTODO DE AZD2171, COMPOSIçãO FARMACêUTICA, KIT MéTODO PARA O TRATAMENTO DE CáNCER EM UM ANIMAL DE SANGUE QUENTE TAL COMO EU SER HUMANO, E, USO DE SAL DE MALEATO DE AZ2171E 5-FU E CPT-11 A presente invenção diz respeito a um método para produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como ser humano que está sendo opcionalmente tratado com radiação ionizante, particularmente um método para o tratamento de um câncer, particulamente um câncer envolvendo um tumor sólido, que compreende a administração de AZD2171 em combinação com 5-FU, CPT-11 ou 5-FU e CPT-11; a uma composição farmacêutica compreendendo AZD2171 e 5-FU, CPT-11 ou 5-FU e CPT-11; aum produto de combinação compreendendo AZD2171 e 5-FU, CPT-11 ou 5-FU, CPT-11 ou 5-FU e CPT-11 para o uso em um método de tratamento de um corpo humano ou animal pela terapia; a um kit compreendendo AZD2171 e 5-FU, CPT-11 ou 5-FU e CPT-11; ao uso de AZD2171 e 5-FU, CPT-11 ou 5-FU e CPT-11 na fabricação de um medicamento para o uso na produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano que está sendo opcionalmente tratado com radiação ionizante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0406446.5A GB0406446D0 (en) | 2004-03-23 | 2004-03-23 | Combination therapy |
PCT/GB2005/001080 WO2005092303A2 (en) | 2004-03-23 | 2005-03-22 | Combination therapy with azd2171 and 5-fu and/or cpt-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0508982A true BRPI0508982A (pt) | 2007-08-28 |
Family
ID=32188482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508982-4A BRPI0508982A (pt) | 2004-03-23 | 2005-03-22 | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080125447A1 (pt) |
EP (1) | EP1729808B1 (pt) |
JP (1) | JP2007530518A (pt) |
KR (1) | KR20060130763A (pt) |
CN (1) | CN1964742A (pt) |
AT (1) | ATE447974T1 (pt) |
AU (1) | AU2005225193B2 (pt) |
BR (1) | BRPI0508982A (pt) |
CA (1) | CA2610628A1 (pt) |
DE (1) | DE602005017591D1 (pt) |
ES (1) | ES2335292T3 (pt) |
GB (1) | GB0406446D0 (pt) |
HK (1) | HK1096023A1 (pt) |
IL (1) | IL177952A0 (pt) |
MX (1) | MXPA06010758A (pt) |
NO (1) | NO20064755L (pt) |
NZ (1) | NZ549553A (pt) |
WO (1) | WO2005092303A2 (pt) |
ZA (1) | ZA200607555B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
WO2005092384A2 (en) * | 2004-03-23 | 2005-10-06 | Astrazeneca Ab | Combination therapy with azd2171 and a platinum anti-tumour agent |
GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
KR20080031029A (ko) * | 2005-07-06 | 2008-04-07 | 아스트라제네카 아베 | Azd2171 및 젬시타빈에 의한 암의 병용 요법 |
DK1965801T3 (da) * | 2005-12-22 | 2011-06-14 | Astrazeneca Ab | Kombination af azd2171 og pemetrexed |
WO2015082880A1 (en) * | 2013-12-02 | 2015-06-11 | Astrazeneca Ab | Methods of selecting treatment regimens |
WO2020061391A1 (en) * | 2018-09-20 | 2020-03-26 | The Trustees Of Columbia University In The City Of New York | Methods for inhibiting tumor cells using inhibitors of foxo3a antagonists |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
SK288365B6 (sk) * | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
LT3143995T (lt) * | 2001-02-19 | 2019-01-25 | Novartis Ag | Rapamicino darinys, skirtas plaučių vėžio gydymui |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
KR20070073813A (ko) * | 2004-09-27 | 2007-07-10 | 아스트라제네카 아베 | Azd2171 및 이마티닙을 포함하는 암의 병합 요법 |
KR20080031029A (ko) * | 2005-07-06 | 2008-04-07 | 아스트라제네카 아베 | Azd2171 및 젬시타빈에 의한 암의 병용 요법 |
CA2633211A1 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
DK1965801T3 (da) * | 2005-12-22 | 2011-06-14 | Astrazeneca Ab | Kombination af azd2171 og pemetrexed |
-
2004
- 2004-03-23 GB GBGB0406446.5A patent/GB0406446D0/en not_active Ceased
-
2005
- 2005-03-22 WO PCT/GB2005/001080 patent/WO2005092303A2/en active Application Filing
- 2005-03-22 AT AT05729381T patent/ATE447974T1/de not_active IP Right Cessation
- 2005-03-22 EP EP05729381A patent/EP1729808B1/en active Active
- 2005-03-22 CN CNA2005800092182A patent/CN1964742A/zh active Pending
- 2005-03-22 MX MXPA06010758A patent/MXPA06010758A/es active IP Right Grant
- 2005-03-22 NZ NZ549553A patent/NZ549553A/en unknown
- 2005-03-22 ES ES05729381T patent/ES2335292T3/es active Active
- 2005-03-22 JP JP2007504467A patent/JP2007530518A/ja active Pending
- 2005-03-22 CA CA002610628A patent/CA2610628A1/en not_active Abandoned
- 2005-03-22 BR BRPI0508982-4A patent/BRPI0508982A/pt not_active IP Right Cessation
- 2005-03-22 AU AU2005225193A patent/AU2005225193B2/en not_active Ceased
- 2005-03-22 KR KR1020067021774A patent/KR20060130763A/ko not_active Application Discontinuation
- 2005-03-22 DE DE602005017591T patent/DE602005017591D1/de active Active
- 2005-03-22 US US10/594,233 patent/US20080125447A1/en not_active Abandoned
-
2006
- 2006-09-07 IL IL177952A patent/IL177952A0/en unknown
- 2006-09-08 ZA ZA200607555A patent/ZA200607555B/en unknown
- 2006-10-20 NO NO20064755A patent/NO20064755L/no not_active Application Discontinuation
-
2007
- 2007-03-20 HK HK07103005.0A patent/HK1096023A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2005092303A3 (en) | 2006-11-02 |
AU2005225193B2 (en) | 2008-10-09 |
DE602005017591D1 (de) | 2009-12-24 |
KR20060130763A (ko) | 2006-12-19 |
ZA200607555B (en) | 2008-05-28 |
EP1729808B1 (en) | 2009-11-11 |
WO2005092303A2 (en) | 2005-10-06 |
NZ549553A (en) | 2009-12-24 |
IL177952A0 (en) | 2007-07-04 |
JP2007530518A (ja) | 2007-11-01 |
HK1096023A1 (en) | 2007-05-25 |
AU2005225193A1 (en) | 2005-10-06 |
NO20064755L (no) | 2006-10-20 |
EP1729808A2 (en) | 2006-12-13 |
CA2610628A1 (en) | 2005-10-06 |
MXPA06010758A (es) | 2006-12-15 |
CN1964742A (zh) | 2007-05-16 |
GB0406446D0 (en) | 2004-04-28 |
ATE447974T1 (de) | 2009-11-15 |
ES2335292T3 (es) | 2010-03-24 |
US20080125447A1 (en) | 2008-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
ATE500832T1 (de) | Kombination von zd6474 und pemetrexed | |
CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
BRPI0508983A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano | |
BRPI0412450A (pt) | métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular em um animal de sangue quente tal como um ser humano, e para o tratamento de um cáncer, composição farmacêutica, kit, e, uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd6126 ou um sal farmaceuticamente aceitável deste | |
BR0315087A (pt) | Métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6126 ou um sal deste farmaceuticamente aceitável e gencitabina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2136 DE 13/12/2011. |